Epidemiology of male osteoporosis and prostate cancer

Current Opinion in Urology

Volumn 15, Issue 1, 2005, Pages 23-27

  Gilbert, Scott M ^a   McKiernan, James M ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Androgen deprivation therapy; Osteoporosis; Prostate cancer

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN; PLACEBO; VITAMIN D; ZOLEDRONIC ACID;

AGING; ANDROGEN THERAPY; BONE DENSITY; BONE MINERALIZATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; FRACTURE; HEALTH CARE COST; HUMAN; HYPOGONADISM; METASTASIS; MORBIDITY; MORTALITY; OSTEOPOROSIS; POPULATION; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; RISK FACTOR; THROMBOEMBOLISM; UNITED STATES;

AGE FACTORS; ANDROGEN ANTAGONISTS; BONE DENSITY; FRACTURES, BONE; HUMANS; MALE; OSTEOPOROSIS; PROSTATIC NEOPLASMS;

EID: 12144265566     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200501000-00006     Document Type: Review

References (41)

1. Lindsay R, Cosman F. Osteoporosis. In: Braunwald E, Fauci AS, Kasper DL, et al., editors. Harrison's principles of internal medicine. Edition 15. New York: McGraw-Hill; 2001. pp. 2226-2237.
2. WHO Study Group on Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: World Health Organization; 1994.
3. Amin S, Felson DT. Osteoporosis in men. Rheum Dis Clin North Am 2001; 27:19-47.
4. Stock H, Schneider A, Strauss E. Osteoporosis: a disease in men. Clin Orthop 2004; 425:143-151.
5. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312:1254-1261.
6. Nguyen TV, Eisman JA, Kelly PJ, Sambrook PN. Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol 1996; 144:255-263.
7. Siddiqui NA, Shetty KR. Osteoporosis in older men: discovering when and how to treat it. Geriatrics 1994; 54:20-37.
8. Kelepouris N, Harper KD, Gannon FM. Severe osteoporosis in men. Ann Intern Med 1995; 123:452.
9. Seeman E, Melton LK. Risk factors for spinal osteoporosis in men. Am J Med 1983; 75:977-983.
10. Falahati-Nini A, Riggs BL, Atkinson EJ, et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000; 106:1553-1560.
11. Khosla S, Melton LJ III, Atkinson EJ, et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998; 83:2266-2274.
12. Jemel A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53:5-26.
13. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000; 88(12 Suppl):2989-2994.
14. Oefelein MG, Resnick MI. The impact of osteoporosis in men treated for prostate cancer. Urol Clin North Am 2004; 31:313-319.
15. Oefelein MG, Ricchuiti V, Conrad W, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001; 166:1724-1728.
16. Diamond TH, Higano CS, Smith MR, et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004; 100:892-899.
17. Kiratli B, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001; 57:127.
18. Wei JT, Gross M, Jaffe CA, et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 1999; 54:607-611.
19. Smith MR, McGovern FJ, Fallon MA, et al. Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer 2001; 91:2238-2245.
20. Conde FA, Sarna L, Oka RK, et al. Age, body mass index, and serum prostate-serun antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology 2004; 64:335-340. This is a prospective report of patients with prostate cancer treated with androgen deprivation therapy who had a high rate of either osteopenia or osteoporosis. There was no control group, and a high percentage of the men were sedentary, so confounding factors may exist and conclusions comparing androgen deprivation therapy with no therapy are difficult to make.
21. Burger H, de Laet CE, van Daele PL, et al. Risk factors for increased bone loss in an elderly population: the Rotterdam study. Am J Epidemiol 1998; 147:871-879.
22. Melton LJ III, Atkinson EJ, O'Fallon WM, et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993; 8:1227-1233.
23. Townsend SF, Sanders WH, Northway RO, et al. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate adenocarcinoma. Cancer 1997; 79:545-550.
24. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157:439-444.
25. Melton LJ, Alothman KI, Khosla S, et al. Fracture risk following bilateral orchiectomy. J Urol 2003; 169:1747-1750.
26. Hatano T, Oishi Y, Furuta A, et al. Incidence of bone fracture in patients receiving luteinizing hormone-releasing agonists for prostate cancer. BJU Int 2000; 86:449-452.
27. Diamond TH, Bucci J, Kersley JH, et al. Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy. Urology 2004; 172:529-532. This is a retrospective review showing a high rate of osteoporosis and symptomatic bone fractures in men with prostate cancer treated with androgen deprivation therapy.
28. Krupski TL, Smith MR, Lee WC, et al. Natural history of bone complications in men with prostate cancer initiating androgen deprivation therapy. Cancer 2004; 101:541-549. Analysis of Medicare beneficiaries revealed that patients with prostate cancer treated with androgen deprivation therapy were at risk for osteoporosis and fracture, although patients treated for greater than 2 years were a significantly increased risk.
29. NIH Consensus Development Panel on Osteoporosis prevention, diagnosis, and therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285:785-795.
30. Kiebzak GM, Beinart GA, Perser K, et al. Under-treatment of osteoporosis in men with hip fracture. Arch Intern Med 2002; 162:2217-2222.
31. Diamond TH, Thornley SW, Sekel R, Smerdely P. Hip fractures in elderly men: prognostic factors and outcomes. Med J Augt 1997; 167:412-415.
32. De Laet CE, Pois HA. Fractures in the elderly: epidemiology and demography. Best Pract Res Clin Endocrinol Metab 2000; 14:171-179.
33. Center JN, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353:878-882.
34. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002; 168:1005-1007.
35. Groot MT, Boeken Kruger CGG, Pelger RCM, Uyl-de Groot CA. Costs of prostate cancer, metastatic to the bone, in The Netherlands. Eur Urol 2003; 43:226-232.
36. Ray NF, Chan JK, Thamer M, Melton LJ 3rd. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12:24-35.
37. Schneider EL, Guralnik JM. The aging of America. Impact on health care costs. JAMA 1990; 263:2335-2340.
38. Scherr D, Pitts WR, Vaughan ED. Diethylstilbestrol revisited: androgen deprivation, osteoporosis and prostate cancer. J Urol 2002; 167:535-538.
39. Ockrim JL, Lalani EN, Laniado ME, et al. Transdermal estradiol therapy for advanced prostate cancer: forward to the past? J Urol 2003; 169:1735-1737.
40. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169:2008-2012. This prospective randomized trial compared zoledronic acid with placebo in patients with prostate cancer treated with androgen deprivation therapy showing a significant increase in bone mineral density in the treatment arm.
41. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468.